Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder

Abstract

EthyL-eicosapentanoic acid (ethyL-EPA) may be beneficial in the treatment of bipolar disorder (BD) and may have a neurotrophic/neuroprotective role in patients with neuropsychiatric disorders. To investigate this we examined whether ethyl-EPA treatment of BD patients is associated with increased brain Levels of N-acetylaspartate (NAA), a putative marker of neuronal integrity. Fourteen female BD outpatients with moderate depressive symptoms were administered 2g of ethyL-EPA per day or placebo for 12 weeks in a randomized, double-blind fashion. Quantitative, proton magnetic resonance spectroscopy imaging data were obtained prior to randomization and after 12 weeks of treatment from a single 12 ml volume of interest centred above the body of the corpus callosum. A significant rise in NAA Levels was observed in the ethyl-EPA treatment group compared with the placebo group (p = 0.027). These results provide the first evidence for a probable neurotrophic role of ethyl-EPA treatment in BD underlining the need for more detailed investigation of its mechanism of action and therapeutic potential.

Keywords

bipolar disorder omega-3 fatty acid eicosapentanoic acid magnetic resonance spectroscopy

Get full access to this article

View all access options for this article.

References

American Psychiatry Association (1994) Diagnostic and Statistical Manual of Mental disorders, 4th edn. American Psychiatric Press, Washington, DC

Armstrong V.T. , Brzustowicz M.R. , Wassall S.R. , Jenski L.J. , Stillwell W. (2003) Rapid flip-flop in polyunsaturated (docosahexaenoate) phospholipid membranes . Arch Biochem Biophys 414: 74—82

Bogazzi F. , Hudson L.D. , Nikodem V.M. (1994) A novel heterodimerization partner for thyroid hormone receptor. Peroxisome proliferator-activated receptor . J Biol Chem 269: 11683—11686

Chakraborty G. , Mekala P. , Yahya D. , Wu G. , Ledeen R.W. (2001) Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase . J Neurochem 78: 736—745

First M.B. , Spitzer R.L. , Gibbon M. , Williams J B W (2001) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). Biometrics Research , New York State Psychiatric Institute, New York

Frangou S. , Lewis M. , McCrone P. (2006) Efficacy of two doses of ethyl eicosapentaenoate (ethyl-EPA) as adjunct therapy in the acute treatment of bipolar 1 depression. Br Journal Psychiatry 188: 46—50

Haldane M. , Frangou S. (2004) New insights help define the pathophysiology of bipolar affective disorder: neuroimaging and neuropathology findings . Prog Neuropsychopharmacol Biol Psychiatry 28: 943—960

Hamilton M. (1960) A rating scale for depression . J Neurol Neurosurg Psychiatry 23: 56—62

MacQueen G.M. , Young L.T. , Joffe R.T. (2001) A review of psychosocial outcome in patients with bipolar disorder . Acta Psychiatr Scand 103: 163—170

10.

Manji H.K. , Moore G.J. , Chen G. ( 1999) Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46: 929—940

11.

Moore G.J. , Bebchuk J.M. , Hasanat K. , Chen G. , Seraji-Bozorgzad N. , Wilds I.B. , Faulk M.W. , Koch S. , Glitz D.A. , Jolkovsky L. , Manji H.K. (2000) Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 48: 1—8

12.

Nemets B. , Stahl Z. , Belmaker R.H. (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder . Am J Psychiatry 159: 477—479

13.

Peet M. , Horrobin D.F. (2002) A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs . Arch Gen Psychiatry 59: 913—919

14.

Provencher S.W. (1993) Estimation of metabolite concentrations from localised in vivo proton NMR spectra . Magn Reson Med 30: 672—679

15.

Puri B.K. , Holmes J. , Hamilton G. (2004) Eicosapentaenoic acid-rich essential fatty acid supplementation in chronic fatigue syndrome associated with symptom remission and structural brain changes . Int J Clin Pract 58: 297—299

16.

Puri B.K. , Counsell S.J. , Hamilton G. , Richardson A.J. , Horrobin D.F. (2001) Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover . Int J Clin Pract 55: 560—563

17.

Puri B.K. , Bydder G.M. , Counsell S.J. , Corridan B.J. , Richardson A.J. , Hajnal J.V. , Appel C. , Mckee H.M. , Vaddadi K.S. , Horrobin D.F. (2002) MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment . Neuroreport 13: 123—126

18.

Saluja I. , Granneman J.G. , Skoff R.P. (2001) PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture . Glia 33: 191—204

19.

Salvati S. , Natali F. , Attorri L. , Raggi C. , Di Biase A , Sanchez M. (2004) Stimulation of myelin proteolipid protein gene expression by eicosapentaenoic acid in C6 glioma cells . Neurochem Int 44: 331—338

20.

Seung Kim H.F. , Weeber E.J. , Sweatt J.D. , Stoll A.L. , Marangell L.B. (2001) Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro . Mol Psychiatry 6: 246—248

21.

Simmons A. , Smail M. , Moore E. , Williams S C R (1998) Serial precision of metabolite peak areas in proton MR spectroscopy of the human brain . Magn Reson Imaging 16: 319—330

22.

Soares J.C. (2003) Contributions from brain imaging to the elucidation of pathophysiology of bipolar disorder . Int J Neuropsychopharmacol 6: 171—180

23.

Stoll A.L. , Severus W.E. (1996) Mood stabilizers: shared mechanisms of action at postsynaptic signal-transduction and kindling processes . Harv Rev Psychiatry 4: 77—89

24.

Stoll A.L. , Severus W.E. , Freeman M.P. , Rueter S. , Zboyan H.A. , Diamond E. , Cress K.K. , Marangell L.B. (1999) Omega-3 fatty acids in bipolar disorder: a preliminary double blind, placebo controlled trial . Arch Gen Psychiatry 56: 407—412

25.

Tkachev D. , Mimmack M.L. , Ryan M.M. , Wayland M. , Freeman T. , Jones P.B. , Starkey M. , Webster M.J. , Yolken R.H. , Bahn S. ( 2003) Global expression-profiling studies and oligodendrocyte dysfunction in schizophrenia and bipolar disorder . Lancet 362: 798—805

26.

Tsai G. , Coyle J.T. (1995) N-acetylaspartate in neuropsychiatric disorders . Prog Neurobiol 46: 531—540